8legs: San antonio breast cancer symposium

Your Followed Topics

#1 out of 25.6K est. views

New analysis of the WISDOM study finds personalized, risk-based screening can be as effective as annual mammograms for detecting breast cancer.
The study enrolled over 28,000 women aged 40 to 74 to test four risk-based screening regimens.
Women at highest risk receive alternating mammograms and MRIs every six months under the risk-based model.
The approach uses a risk algorithm incorporating genetic data, breast density, age, and family history.
Esserman says risk-based screening is a prerequisite to implementation and aims to reduce over-treatment.
Early results suggest fewer higher-stage cancers (Stage 2B) in the highest-risk group compared with annual screening.
Experts note that risk-based screening could prevent over-treatment and tailor prevention efforts.
The research underscores the role of routine genetic testing in identifying high-risk individuals early.
WISDOM will continue to track treatments and outcomes as it advances risk-based screening.

Vote 0

#2 out of 2

New study in BRCA mutation carriers finds menopausal hormone therapy did not increase breast cancer risk over ~5.6 years of follow-up.
Estrogen-only MHT was linked to a 63% lower breast cancer risk compared with non-MHT users among BRCA mutation carriers.
Conjugated estrogen and bazedoxifene showed no cancer cases among participants in the study.
Researchers call for a personalized approach to menopause management for BRCA mutation carriers.
Study presented at the San Antonio Breast Cancer Symposium highlights potential safety of MHT for BRCA carriers.
Researchers analyzed 676 matched pairs to compare MHT users and non-users among BRCA mutation carriers.
The general population findings that linked MHT to breast cancer risk are being reconsidered for BRCA mutation carriers.
Kotsopoulos emphasizes education for patients and providers on balancing MHT risks and benefits.
The study supports continuing MHT for menopausal relief in eligible BRCA mutation carriers with careful monitoring.
Media coverage on BRCA and MHT evolves as new data emerge, challenging earlier warnings.

Vote 0

Unlimited Access

Personalized Feed

Full Experience

By continuing, you agree to the Privacy Policy.. You also agree to receive our newsletters, you can opt-out any time.

Create an account and enjoy content that interests you with your personalized feed

Unlimited Access

Personalized Feed

Full Experience

By continuing, you agree to the Privacy Policy.. You also agree to receive our newsletters, you can opt-out any time.